4//SEC Filing
XTL BIOPHARMACEUTICALS LTD 4
Accession 0000909012-08-000731
$XTLBCIK 0001023549other
Filed
Jun 18, 8:00 PM ET
Accepted
Jun 19, 12:37 PM ET
Size
15.4 KB
Accession
0000909012-08-000731
Insider Transaction Report
Form 4
EDELMAN JOSEPH
10% Owner
Transactions
- Purchase
Ordinary Shares
2008-06-10$3.23/sh+2,040$6,589→ 3,072,560 total(indirect: see footnote) - Purchase
Ordinary Shares
2008-06-10$3.23/sh+48,960$158,141→ 57,558,070 total(indirect: see footnote)
Transactions
- Purchase
Ordinary Shares
2008-06-10$3.23/sh+2,040$6,589→ 3,072,560 total(indirect: see footnote) - Purchase
Ordinary Shares
2008-06-10$3.23/sh+48,960$158,141→ 57,558,070 total(indirect: see footnote)
Bradley Scott
10% Owner
Transactions
- Purchase
Ordinary Shares
2008-06-10$3.23/sh+48,960$158,141→ 57,558,070 total(indirect: see footnote) - Purchase
Ordinary Shares
2008-06-10$3.23/sh+2,040$6,589→ 3,072,560 total(indirect: see footnote)
Cho Michael
10% Owner
Transactions
- Purchase
Ordinary Shares
2008-06-10$3.23/sh+48,960$158,141→ 57,558,070 total(indirect: see footnote) - Purchase
Ordinary Shares
2008-06-10$3.23/sh+2,040$6,589→ 3,072,560 total(indirect: see footnote)
PERCEPTIVE ADVISORS LLC
10% Owner
Transactions
- Purchase
Ordinary Shares
2008-06-10$3.23/sh+2,040$6,589→ 3,072,560 total(indirect: see footnote) - Purchase
Ordinary Shares
2008-06-10$3.23/sh+48,960$158,141→ 57,558,070 total(indirect: see footnote)
Footnotes (3)
- [F1]This Form 4 is being filed by Joseph Edelman, Michael Cho, Scott Bradley, Perceptive Life Science Master Fund Ltd. ("Master Fund") and Perceptive Advisors LLC ("Advisors").
- [F2]This transaction was effected through the Master Fund. Mr. Edelman is the managing member of Advisors, which in turn serves as the investment manager of Master fund. Mr. Edelman and Mr. Bradley share dispositive power over 1,010,000 of such shares and Mr. Edelman and Mr. Cho share dispositive power of 2,696,450 of such shares. Mr. Edelman has sole voting and dispositive power of the remainder of such shares. In accordance with Instruction 4(b)(iv) of Form 4, the entire amount of the Issuer's securities held by Master Fund is reported herein. Each of Mr. Edelman, Mr. Cho, Mr. Bradley and Advisors disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary therein, and this report shall not be deemed an admission that Mr. Edelman, Mr. Cho, Mr. Bradley and Advisors is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- [F3]This transaction was effected through an account at First New York Trading, LLC. Mr. Edelman and Mr. Cho share dispositive power over 299,570 of such shares and Mr. Edelman has sole voting and dispositive power over the remainder of such shares. Mr. Edelman and Mr. Cho each disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman or Mr. Cho is the beneficial owner of such securities for purposes of Sectioin 16 or for any other purposes. Mr. "Bradley disclaims beneficial ownership over all such shares.
Documents
Issuer
XTL BIOPHARMACEUTICALS LTD
CIK 0001023549
Entity typeother
IncorporatedIsrael
Related Parties
1- filerCIK 0001023549
Filing Metadata
- Form type
- 4
- Filed
- Jun 18, 8:00 PM ET
- Accepted
- Jun 19, 12:37 PM ET
- Size
- 15.4 KB